MedPac to Congress: Make pharmas report all samples to HHS

Share this article:
MedPac, the congressional advisory commission on Medicare, has endorsed stringent transparency rules for drug, device and biologics manufacturers, including detailed reporting on drug samples with the aim of facilitating targeted counter-detailing.  

The commission voted Thursday to recommend that Congress require manufacturers to report financial relationships with: “Physicians, physician groups and other prescribers; pharmacies and pharmacists; health plans, pharmacy benefit managers and their employees; hospitals and medical schools; organizations that sponsor continuing medical education” and patient and professional organizations.

Under MedPac's proposal, companies would be required to submit information on their relationships to the Secretary of the Department of Health and Human Services, who would post it online in a format searchable by manufacturer, recipient name, location and specialty, type of payment, name of the relevant drug or device and year.

In addition, manufacturers and distributors of drugs would be required to report the name and business address of each recipient of samples, along with the name, dosage and number of units of each sample and the date of distribution.

All hospitals and other entities that bill Medicare for services would be required to issue annual reports on physician ownership of interest in non-publicly traded hospitals and practices, and the HHS Secretary would be required to submit a report on the types and prevalence of financial arrangements between hospitals and physicians.

Tom Sullivan, president of med ed firm Rockpointe and proprietor of the Policy and Medicine blog, noted the heavy managed care representation on the committee, and said managed care is looking to squeeze doctors and drug companies to save its skin. “Payers are anxious to gain access to this information for negotiation purposes, to help drive down the cost of healthcare,” said Sullivan. “With this information, they would have a treasure trove of data and they would be able to counter-detail.”

At last week's meeting, commissioner John Bertko, a former chief actuary at Humana who is now a visiting scholar at the Brookings Institute and adjunct staff at the RAND Corp. think tank, said, with respect to the provision on reporting of sampling: “I think it could still be useful in the sense that if you're looking for counter-detailing, a [pharmacy benefit manager] or [prescription drug plan] would know who the paid scripts were for, and they could look backward and see where the samples went and generated the paid scripts and know that that's the time to do the counter-detailing. So it would be kind of a retrospective look at these things, and it would be useful.”
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...